Renal osteodystrophy in children undergoing continuous ambulatory peritoneal dialysis

Area of Science:

• Pediatric Nephrology
• Mineral and Bone Disorders

Background:

• Renal bone disease is a common complication in children with end-stage renal disease.
• Continuous ambulatory peritoneal dialysis (CAPD) is a treatment option for pediatric patients with end-stage renal disease.
• Management of mineral and bone disorders during CAPD is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the course of renal bone disease in children treated with CAPD.
• To identify factors influencing bone disease progression in pediatric CAPD patients.
• To investigate the role of serum calcium and parathyroid hormone levels in renal osteodystrophy during CAPD.

Main Methods:

• Retrospective evaluation of 14 children undergoing CAPD.
• Division of patients into two groups based on serum alkaline phosphatase activity changes.
• Serial radiological examinations and biochemical assessments (serum calcium, parathyroid hormone).

Main Results:

• Patients with decreased/stable alkaline phosphatase (Group I) showed adequate control of renal osteodystrophy.
• Patients with rising alkaline phosphatase (Group II) had no improvement or worsening of bone disease.
• Group I had higher serum calcium and lower parathyroid hormone levels than Group II, despite similar vitamin D metabolite dosage.

Conclusions:

• Higher serum calcium levels (frequently >2.62 mmol/liter) appear protective against radiological progression of secondary hyperparathyroidism in pediatric CAPD patients.
• Lower serum calcium levels (2.25-2.50 mmol/liter) did not lead to regression of secondary hyperparathyroidism.
• Altered "set-point" regulation of the parathyroid gland may exist in children undergoing CAPD, influencing bone disease management.